Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Sanofi-Aventis Stories

2012-06-15 23:03:13

Parker Waichman LLP has filed three lawsuits on behalf of the estates of victims who suffered fatal gastrointestinal and/or cerebral hemorrhaging allegedly due to the blood thinner, Plavix. (PRWEB) June 15, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed lawsuits alleging Bristol-Myers Squibb and Sanofi-Aventis´ Plavix caused the wrongful deaths of three patients. The suits were filed on May 30th in the...

2012-06-15 06:23:51

Sanofi US Pledges $800,000 to Support Healthy Schools in New Jersey and Commits to Follow Recommendations Providing Childhood Obesity Healthcare Benefits to All Sanofi US Employees NEW YORK, June 15, 2012 /PRNewswire-USNewswire/ -- Sanofi US (Sanofi) and the Alliance for a Healthier Generation, a non-profit organization founded by the American Heart Association and the William J. Clinton Foundation, today announced a new model for the private sector to combat childhood obesity. Sanofi...

2012-06-11 10:24:37

PARIS, France, June 11, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States, providing further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus® (insulin glargine [rDNA origin]...

2012-06-05 02:28:01

New resource provides complete and practical information for prostate cancer patients and their families MONTREAL, June 5, 2012 /CNW Telbec/ - "You have prostate cancer" are four words that can instantly change a man's life. Future plans and next steps may seem insurmountable as the newly diagnosed patient wades through information that may be complicated or inaccurate. A new resource, authored by two renowned urologists and researchers, Dr. Fred Saad and Dr. Michael McCormack, and...

2012-05-29 10:24:58

Innovative web-based platform will help educate, empower and encourage Canadians living with diabetes to more effectively manage their disease MONTREAL, May 29, 2012 /CNW/ - TELUS Health has partnered with Sanofi Canada to launch STARsystem, an innovative private web-based platform that gives diabetics free anywhere, anytime access to personalized education and self-management health tools. The STARsystem platform is available to diabetics who purchase BGStar and iBGStar blood...

2012-05-17 10:25:14

PITTSBURGH, May 17, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg. The company was the first to have filed a substantially complete ANDA containing a Paragraph IV certification to the FDA for Clopidogrel Tablets, 300 mg, and was awarded 180 days of marketing...

2012-05-08 02:28:27

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- The new prescription sleep aid Intermezzo (zolpidem tartrate) sublingual tablet CIV is the first and only prescription sleep aid approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, and the patient has at least four hours of bedtime remaining before the planned time of waking. Intermezzo has gender-specific dosing (1.75 mg for adult...

2012-05-02 02:27:41

BRIDGEWATER, N.J., May 2, 2012 /PRNewswire/ -- Sanofi US announced today that the iBGStar® Blood Glucose Monitoring System, consisting of the iBGStar® blood glucose meter and iBGStar® Diabetes Manager App, is commercially available in the U.S. iBGStar® is the first Food and Drug Administration (FDA) cleared blood glucose meter that directly connects to the iPhone® and iPod touch®, offering accurate blood glucose monitoring that seamlessly integrates into the lives of...

2012-05-02 02:26:44

OXFORD, England, May 2, 2012 /PRNewswire/ -- Oxford BioTherapeutics (OBT) today announces the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this position he will lead the company's newly created clinical development operations based in Basel, Switzerland. The establishment of a dedicated development operation represents a key milestone in OBT's global expansion as it progresses its most advanced therapeutic antibody and antibody...

2012-04-27 02:25:48

PARIS, April 27, 2012 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Q1 2012 Change on a Change at constant reported basis exchange rates -------------- -------------- Net sales euro 8,511m +9.4% +7.0% Business net income(1) euro 2,442m +12.5% +8.4%...